- Home
- ABEO vs CLLS Comparison
ABEO vs CLLS Comparison
Compare ABEO & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ABEO | CLLS |
|---|---|---|
| Founded | 1974 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 399.5M | 394.4M |
| IPO Year | 2005 | 2014 |
Fundamental Metrics
Financial Performance| Metric | ABEO | CLLS |
|---|---|---|
| Price | $6.07 | $3.21 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $20.00 | $8.33 |
| AVG Volume (30 Days) | ★ 1.6M | 16.7K |
| Earning Date | 05-13-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 165.16 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,998,000.00 | N/A |
| Revenue This Year | $1,024.31 | N/A |
| Revenue Next Year | $145.42 | $0.98 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 258.18 | N/A |
| 52 Week Low | $4.00 | $2.35 |
| 52 Week High | $7.65 | $5.48 |
Technical Indicators
Market Signals| Indicator | ABEO | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 42.92 | 56.29 |
| Support Level | $5.68 | $2.94 |
| Resistance Level | $7.51 | $3.40 |
| Average True Range (ATR) | 0.31 | 0.17 |
| MACD | -0.11 | 0.06 |
| Stochastic Oscillator | 19.23 | 75.22 |
Price Performance
Historical ComparisonAbout ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.